Next Article in Journal / Special Issue
Reply to Chen, A.; Zhang, X. Comment on “Golčić et al. Evaluation of Systemic Treatment Options for Gastrointestinal Stromal Tumours. Cancers 2023, 15, 4081”
Previous Article in Journal
Review of Current Treatment Intensification Strategies for Prostate Cancer Patients
Previous Article in Special Issue
Personalized Therapy of Sarcomas
 
 
Comment
Peer-Review Record

Comment on Golčić et al. Evaluation of Systemic Treatment Options for Gastrointestinal Stromal Tumours. Cancers 2023, 15, 4081

Cancers 2023, 15(23), 5618; https://doi.org/10.3390/cancers15235618
by Anni Chen and Xinhua Zhang *
Reviewer 1:
Reviewer 2:
Cancers 2023, 15(23), 5618; https://doi.org/10.3390/cancers15235618
Submission received: 13 September 2023 / Revised: 28 October 2023 / Accepted: 15 November 2023 / Published: 28 November 2023
(This article belongs to the Special Issue Personalized Therapy of Sarcomas)

Round 1

Reviewer 1 Report

Comments and Suggestions for Authors

Thank you for asking me to review this. I think that the authors make a valid point that is worth publishing to highlight the difference between dose escalation and switching drugs. I agree that dose escalation shouldn't be classified as second line therapy. 

Author Response

Dear reviewer, Thanks very much for taking your time to review this manuscript. We are grateful for your positive feedback.

Reviewer 2 Report

Comments and Suggestions for Authors

I agree with the commentary, increase of imatinib should not be considered as second line therapy formally, it can be even used upfront in exon 9 KIT mutants. ESMO and NCCN definition/guidelines are correctly intepreted and cited. I propose to add the remark about the use of Italics for gene names what is not implemented in part of the original article.

Author Response

Dear reviewer, Thank you for your suggestion. We appreciate your time and effort in reviewing our manuscript. We have considered your comment and have made the necessary revision to address it.  The revision has been highlighted in yellow. We hope that the revised manuscript meets your expectation and look forward to hearing from you again.

Author Response File: Author Response.docx

Back to TopTop